Sun Pharma, India's largest drug company has rolled out InfuSMART the first ever ready to administer version of anti cancer drug gemcitabine in six countries of Europe including Netherlands, UK, Spain, Germany, Italy and France.
Takeda and Theravance Biopharma, Inc. announced that the companies have entered into a global license, development and commercialization agreement for TD-8954, a selective 5-HT4 receptor agonist being investigated for potential use in the treatment of gastrointestinal motility disorders, including enteral feeding intolerance (“EFI”).
Amgen announced that The Lancet published results from a Phase 3 randomized, double-blind, placebo-controlled study of Nplate in children with symptomatic immune thrombocytopenia.
- New studies will evaluate the effect of JARDIANCE for the treatment of chronic heart failure
- There are approximately 26 million people worldwide, and 5.7 million people in the U.S., suffering from chronic heart failure
- The studies build on results from the landmark EMPA-REG OUTCOME® trial
GSK presented new data for its meningococcal group B vaccine, Bexsero®,1 [Meningococcal group B Vaccine (rDNA, component, adsorbed)] comparing safety and immunogenicity with different dosing schedules in infants and young children, at the annual meeting of the European Society for Paediatric Infectious Diseases (ESPID).
FIrst PCSK9 Inhibitor in Japan,Providing A new TREATMENT option for certain patients who have high risk in cardiovascular events and do not adequately respond to statins.
Only Manufacturer to Offer the Antibiotic in a Ready-to-Use Premixed Presentation